PRESS RELEASE published on 03/18/2026 at 10:15, 1 month 12 days ago Inside Information / Other news releases GenSight Biologics closes nearly €1.7 million fundraising for developing gene therapies in ophthalmology and CNS disorders. Contact: CFO Jan Eryk Umiastowski Fundraising Ophthalmology GenSight Biologics Gene Therapies CNS Disorders
BRIEF published on 03/10/2026 at 09:05, 1 month 20 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 1 month 20 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 1 month 21 days ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 1 month 21 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
PRESS RELEASE published on 03/09/2026 at 07:30, 1 month 21 days ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
BRIEF published on 02/18/2026 at 07:35, 2 months 12 days ago GenSight Biologics Strengthens its Regulatory Team Phase III Trial Regulatory Affairs Key Appointments GenSight Biologics Gene Therapies
BRIEF published on 02/18/2026 at 07:35, 2 months 12 days ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
PRESS RELEASE published on 02/18/2026 at 07:30, 2 months 12 days ago Inside Information / Other news releases GenSight Biologics strengthens Regulatory Affairs & Quality team with two key appointments to support global regulatory strategy and upcoming milestones in gene therapy for retinal diseases Quality Regulatory Affairs GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 02/10/2026 at 07:35, 2 months 20 days ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
Published on 04/30/2026 at 21:00, 46 minutes ago Datavault AI Schedules Conference Call to Discuss First Quarter 2026 Financial Results on Friday, May 15, 2026
Published on 04/30/2026 at 19:00, 2 hours 46 minutes ago Caldwell Announces Appointment of Shawn Banerji as Co-Leader of Technology Practice
Published on 04/30/2026 at 16:00, 5 hours 46 minutes ago CORRECTION FROM SOURCE: Rio Grande Resources Announces Results from its Airborne Survey at Winston Gold/Silver Project, New Mexico and Announces New President
Published on 04/30/2026 at 15:35, 6 hours 11 minutes ago Nepra Foods Enters Letter of Intent to Acquire Idaho Bottling and Water Assets, Advancing Vertical Integration Strategy
Published on 04/30/2026 at 15:10, 6 hours 36 minutes ago Formation Metals Announces Non-Brokered Offering of up to $15 Million Fully Allocated
Published on 04/30/2026 at 19:00, 2 hours 46 minutes ago DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 19:00, 2 hours 46 minutes ago BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Published on 04/30/2026 at 18:59, 2 hours 47 minutes ago Sirma Group Holding published its Invitation for Annual Regular General Shareholder Meeting
Published on 04/30/2026 at 18:41, 3 hours 5 minutes ago Ørsted completes divestment of its European onshore business
Published on 04/30/2026 at 18:41, 3 hours 5 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 04/30/2026 at 20:00, 1 hour 46 minutes ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 2 hours 30 minutes ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 2 hours 46 minutes ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 3 hours 36 minutes ago Minutes of the Combined General Meeting held on April 30, 2026
